T 2570/11 (IL-17 inhibition/UCB) of 12.07.2017
- European Case Law Identifier
- ECLI:EP:BA:2017:T257011.20170712
- Date of decision
- 12 July 2017
- Case number
- T 2570/11
- Petition for review of
- -
- Application number
- 04798568.4
- IPC class
- A61P 37/00A61K 47/48A61K 39/395
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Method for the treatment of multiple sclerosis by inhibiting IL-17 activity
- Applicant name
- UCB Pharma, S.A.
- Opponent name
- 01: Eli Lilly & Co.
02: Merck Serono S.A.
03: Schering Corporation
04: Genentech, Inc. - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 56
- Keywords
- Inventive step - (no)
- Catchword
- -
- Cited cases
- -
- Citing cases
- T 0217/15
Order
For these reasons it is decided that:
The appeal is dismissed.